Program
lopinavir-ritonavir drug combination
Also written as “Lopinavir/Ritonavir”, “Lopinavir/ritonavir” and “lopinavir/ritonavir”.
Its studies are mostly in HIV Infections · Hepatitis C · Papilloma · Acquired Immunodeficiency Syndrome · Infections, led by 5 companies.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Abbott | 120 open or running | phase 4since Sep 13, 2005 | Nov 2, 1999 | none ahead |
| AbbVie | 20 open or running | phase 4since Sep 13, 2005 | Sep 13, 2005 | none ahead |
| Daré Bioscience | 11 open or running | phase 2since May 15, 2026 | May 15, 2026 | Oct 2027phase 2 · NCT07601074 |
| virx | 10 open or running | phase 2since Nov 2, 1999 | Nov 2, 1999 | none ahead |
| World Medicine ILAC SAN. ve TIC. A.S. | 10 open or running | phase 1since May 5, 2020 | May 5, 2020 | none ahead |
Also a collaborator on its studies: Basilea Pharmaceutica International and Shionogi.
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
Before these, 3 studies since Nov 2, 1999.
- Nov 2, 1999Phase 1 study in HIV InfectionsAbbott · NCT00004580 · United States
- Nov 2, 1999Phase 2 study in HIV InfectionsAbbott · NCT00004578 · 100 enrolled · United States
- May 29, 2002Phase 2 study in HIV InfectionsAbbott · NCT00038220 · 40 enrolled · United States
- Jun 3, 2002Phase 3 study in HIV InfectionsAbbott · NCT00038636 · 36 enrolled · United States, France, Spain
- Aug 15, 2002Phase 3 study in HIV InfectionsAbbott · NCT00043966 · 200 enrolled · United States, Australia, France and more
- Aug 15, 2002Phase 2 study in HIV InfectionsAbbott · NCT00043953 · 30 enrolled · United States, Canada
- Jan 6, 2004Phase 2 study in HIV InfectionsAbbott · NCT00075231 · 150 enrolled · United States
- Jul 14, 2005Phase 2 study in HIV InfectionsAbbott · NCT00121017 · 200 enrolled
- Sep 13, 2005AbbVie’s first study: phase 4 study in HIV InfectionsNew to AbbVieAbbVie · NCT00234975 · 86 enrolled · Puerto Rico
- Sep 13, 2005Phase 4 study in HIV InfectionsAbbott · NCT00234962 · 200 enrolled · United States
- Mar 28, 2008Phase 4 study in Acquired Immunodeficiency SyndromeAbbVie · NCT00648999 · 207 enrolled · Mexico
- Aug 27, 2008Phase 1 study in TuberculosisAbbott · NCT00743470 · 15 enrolled · United States
- May 5, 2020World Medicine ILAC SAN. ve TIC. A.S.’s first study: phase 1 study in BioequivalenceNew to World Medicine ILAC SAN. ve TIC. A.S.World Medicine ILAC SAN. ve TIC. A.S. · NCT04386876 · 30 enrolled · Turkey
- May 15, 2026Daré Bioscience’s first study: phase 2 study in Human Papilloma Virus (HPV)New to Daré BioscienceDaré Bioscience · NCT07601074 · 118 planned · United States
Ahead
- Oct 2027Primary completion: phase 2 study in Human Papilloma Virus (HPV)Daré Bioscience · NCT07601074
TargetBeta
Not stated by its company or a source we have read. Most early programs say nothing of it.
Studies
All 17 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Led by | Primary completion | Size |
|---|---|---|---|---|---|
| NCT07601074Human Papilloma Virus (HPV) · United States | 2 | Recruiting | Daré Bioscience | Oct 2027 | 118 |
| NCT04386876Bioequivalence · Turkey | 1 | Completed | World Medicine ILAC SAN. ve TIC. A.S. | May 22, 2020 | 30 |
| NCT00743470Tuberculosis · United States | 1 | Terminated | Abbott | Oct 2008 | 15 |
| NCT00648999Acquired Immunodeficiency Syndrome · Mexico | 4 | Completed | AbbVie | Dec 2006 | 207 |
| NCT00234975HIV Infections · Puerto Rico | 4 | Completed | AbbVie | Jan 2008 | 86 |
| NCT00234962HIV Infections · United States | 4 | Terminated | Abbott | 200 | |
| NCT00121017HIV Infections | 2 | Withdrawn | Abbott | 200 | |
| NCT00075231HIV Infections · United States | 2 | Completed | Abbott | 150 | |
| NCT00043966HIV Infections · United States, Australia, France and more | 3 | Completed | Abbott | 200 | |
| NCT00043953HIV Infections · United States, Canada | 2 | Completed | Abbott | 30 | |
| NCT00038636HIV Infections · United States, France, Spain | 3 | Completed | Abbott | 36 | |
| NCT00038220HIV Infections · United States | 2 | Completed | Abbott | 40 | |
| NCT00004583HIV Infections · United States, Australia, Austria and more | 3 | Completed | Abbott | 660 | |
| NCT00004582HIV Infections · United States | 2 | Completed | virx | ||
| NCT00004581HIV Infections · United States, Australia, Austria and more | 3 | Completed | Abbott | 300 | |
| NCT00004580HIV Infections · United States | 1 | Completed | Abbott | ||
| NCT00004578HIV Infections · United States | 2 | Completed | Abbott | Apr 2005 | 100 |
How it is read
Names in the registry
- “Lopinavir/Ritonavir”, 11 entries
- “Lopinavir/ritonavir”, 7 entries
- “lopinavir/ritonavir”, 3 entries
- “Kaletra (lopinavir/ritonavir)”, 2 entries
- “Lopinavir / ritonavir”, 1 entry
Conditions, from the studies’ own filings
- HIV Infections, 19 studies
- Hepatitis C, 2 studies
- Papilloma, 1 study
- Acquired Immunodeficiency Syndrome, 1 study
- Infections, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.